Cumulative costs over the 6 months follow-up period by condition (CBTsa vs TAU), in 2015 Euros.

Cumulative breast cancer treatment costs by stages of in situ, local, regional and distant.

Li Sun (4624)
Rosa Legood (362486)
Isabel dos-Santos-Silva (528117)
Shivani Mathur Gaiha (6009653)
Zia Sadique (3487259)

November 2018

Cumulative breast cancer treatment costs by stages of in situ, local, regional and distant.</p

Observed mean annual costs per patient with chronic pain by sex and number of pain points (in EUR for year 2016) (n = 54).

Susanne Mayer (3532715)
Jonah Spickschen (6490565)
K. Viktoria Stein (6490568)
Richard Crevenna (4976600)
Thomas E. Dorner (748649)
Judit Simon (4353796)

March 2019

Observed mean annual costs per patient with chronic pain by sex and number of pain points (in EUR fo...

Multiple imputed, unadjusted costs used by participants allocated to the EuroFIT programme immediately (intervention) or after 12 months (comparison), and their unit costs (£, 2016) over 12-month follow-up.

Sally Wyke (3408131)
Christopher Bunn (5467193)
Eivind Andersen (6298112)
Marlene N. Silva (6298115)
Femke van Nassau (4518406)
Paula McSkimming (6298118)
Spyros Kolovos (6298121)
Jason M. R. Gill (206415)
Cindy M. Gray (6298124)
Kate Hunt (596973)
Annie S. Anderson (6298127)
Judith Bosmans (444246)
Judith G. M. Jelsma (6298130)
Sharon Kean (458309)
Nicolas Lemyre (6298133)
David W. Loudon (6298136)
Lisa Macaulay (6298139)
Douglas J. Maxwell (6298142)
Alex McConnachie (104022)
Nanette Mutrie (53509)
Maria Nijhuis-van der Sanden (3506987)
Hugo V. Pereira (6298145)
Matthew Philpott (6298148)
Glyn C. Roberts (6298151)
John Rooksby (6298154)
Øystein B. Røynesdal (6298157)
Naveed Sattar (8785)
Marit Sørensen (6298160)
Pedro J. Teixeira (848483)
Shaun Treweek (62880)
Theo van Achterberg (5454581)
Irene van de Glind (6298163)
Willem van Mechelen (17577)
Hidde P. van der Ploeg (484286)

February 2019

Multiple imputed, unadjusted costs used by participants allocated to the EuroFIT programme immediate...

Valuation of cost items during the 12-month follow-up period (in Euro; 2016).

Ben F. M. Wijnen (4997315)
Bea Hemmen (3633202)
Ans I. E. Bouman (3633208)
Henk van de Meent (731131)
Ton Ambergen (295464)
Peter R. G. Brink (3633211)
Henk A. M. Seelen (563131)
Silvia M. A. A. Evers (643477)

March 2019

Valuation of cost items during the 12-month follow-up period (in Euro; 2016).</p

Basic characteristics and cumulative breast cancer treatment costs by stage (US dollars in 2015).

Li Sun (4624)
Rosa Legood (362486)
Isabel dos-Santos-Silva (528117)
Shivani Mathur Gaiha (6009653)
Zia Sadique (3487259)

November 2018

Basic characteristics and cumulative breast cancer treatment costs by stage (US dollars in 2015).</p

Costs and “extra costs” of brand, follow-on, generic, and total prescriptions in millions of Euros.

Nathalie Vernaz (289981)
Guy Haller (418190)
François Girardin (418191)
Benedikt Huttner (322756)
Christophe Combescure (146642)
Pierre Dayer (418192)
Daniel Muscionico (418193)
Jean-Luc Salomon (418194)
Pascal Bonnabry (418195)

June 2013

Costs and “extra costs” of brand, follow-on, generic, and total prescriptions in millions of Euro...

Cumulative cost of care ($CAD 2018, 95% CI) between sepsis cases and matched controls.

Michelle Tew (8725419)
Kim Dalziel (5237753)
Karin Thursky (4329955)
Murray Krahn (250684)
Lusine Abrahamyan (6291005)
Andrew M. Morris (4249600)
Philip Clarke (78600)

August 2021

Cumulative cost of care ($CAD 2018, 95% CI) between sepsis cases and matched controls.</p

“Extra costs” in millions of Euros, 95% CIs, and percent of total prescriptions for three scenarios.

Nathalie Vernaz (289981)
Guy Haller (418190)
François Girardin (418191)
Benedikt Huttner (322756)
Christophe Combescure (146642)
Pierre Dayer (418192)
Daniel Muscionico (418193)
Jean-Luc Salomon (418194)
Pascal Bonnabry (418195)

June 2013

“Extra costs” in millions of Euros, 95% CIs, and percent of total prescriptions for three scenari...

Cumulative outpatient main healthcare care costs since the index dates in different health states of HER2-positive breast cancer in Iran, during a 3-year follow-up period (21.3.2011–20.3.2014).

Amir Ansaripour (5807627)
Kazem Zendehdel (731058)
Niki Tadayon (5807630)
Fatemeh Sadeghi (832474)
Carin A. Uyl-de Groot (4370503)
W. Ken Redekop (5807633)

October 2018

Cumulative outpatient main healthcare care costs since the index dates in different health states of...

Differences in relapse or recurrence and costs over 12 months between S-PCT and TAU; ICER, CE-planes quadrants, and acceptability.

Karolien E. M. Biesheuvel-Leliefeld (6103085)
Judith E. Bosmans (162999)
Sandra M. A. Dijkstra-Kersten (6103088)
Filip Smit (186016)
Claudi L. H. Bockting (130818)
Digna J. F. van Schaik (6103091)
Harm W. J. van Marwijk (145838)
Henriette E. van der Horst (6103094)

December 2018

Differences in relapse or recurrence and costs over 12 months between S-PCT and TAU; ICER, CE-planes...

Observed mean annual costs per patient with chronic pain (in EUR for year 2016): Main analysis (n = 54) and sensitivity analysis (n = 33).

Susanne Mayer (3532715)
Jonah Spickschen (6490565)
K. Viktoria Stein (6490568)
Richard Crevenna (4976600)
Thomas E. Dorner (748649)
Judit Simon (4353796)

March 2019

Observed mean annual costs per patient with chronic pain (in EUR for year 2016): Main analysis (n = ...

Adjusted differences in mean yearly cumulative costs, treated vs. untreated, by cohort.

Bryan S. Michalowicz (16827899)
Jeffrey P. Anderson (16827902)
Thomas E. Kottke (13875140)
Steven P. Dehmer (6528569)
Donald C. Worley (15219980)
Sheryl Kane (16827905)
Sarah Basile (16827908)
D. Brad Rindal (12375537)

August 2023

Adjusted differences in mean yearly cumulative costs, treated vs. untreated, by cohort.</p

Felix Lötsch (625051)
Christine M. Budke (116245)
Herbert Auer (14621)
Klaus Kaczirek (811816)
Fredrik Waneck (6281387)
Heimo Lagler (297548)
Michael Ramharter (297552)

January 2019

Average AE-related costs in the year of diagnosis and the two subsequent years.</p

Multiple imputed and pooled costs after 6 months follow-up in the usual care and interventioun groups and mean differences between groups (95% CI) (unadjusted analysis).

Maria Rubio-Valera (444245)
Judith Bosmans (444246)
Ana Fernández (309521)
Maite Peñarrubia-María (444247)
Marian March (444248)
Pere Travé (444249)
Juan A. Bellón (444250)
Antoni Serrano-Blanco (87615)

August 2013

Multiple imputed and pooled costs after 6 months follow-up in the usual care and interventioun gr...

Cost-effectiveness acceptability curve showing probability that JCP+TAU is more cost-effective than TAU over 18-months follow-up.

Barbara Barrett (489210)
Waquas Waheed (489211)
Simone Farrelly (489212)
Max Birchwood (489213)
Graham Dunn (489214)
Clare Flach (489215)
Claire Henderson (489216)
Morven Leese (489217)
Helen Lester (164644)
Max Marshall (489218)
Diana Rose (342126)
Kim Sutherby (489219)
George Szmukler (489220)
Graham Thornicroft (44441)
Sarah Byford (405086)

November 2013

Cost-effectiveness acceptability curve showing probability that JCP+TAU is more cost-effective th...

Cumulative breast cancer treatment costs by stages of in situ, local, regional and distant.

Li Sun (4624)
Rosa Legood (362486)
Isabel dos-Santos-Silva (528117)
Shivani Mathur Gaiha (6009653)
Zia Sadique (3487259)

November 2018

Cumulative breast cancer treatment costs by stages of in situ, local, regional and distant.</p

Observed mean annual costs per patient with chronic pain by sex and number of pain points (in EUR for year 2016) (n = 54).

Susanne Mayer (3532715)
Jonah Spickschen (6490565)
K. Viktoria Stein (6490568)
Richard Crevenna (4976600)
Thomas E. Dorner (748649)
Judit Simon (4353796)

March 2019

Observed mean annual costs per patient with chronic pain by sex and number of pain points (in EUR fo...

Multiple imputed, unadjusted costs used by participants allocated to the EuroFIT programme immediately (intervention) or after 12 months (comparison), and their unit costs (£, 2016) over 12-month follow-up.

Sally Wyke (3408131)
Christopher Bunn (5467193)
Eivind Andersen (6298112)
Marlene N. Silva (6298115)
Femke van Nassau (4518406)
Paula McSkimming (6298118)
Spyros Kolovos (6298121)
Jason M. R. Gill (206415)
Cindy M. Gray (6298124)
Kate Hunt (596973)
Annie S. Anderson (6298127)
Judith Bosmans (444246)
Judith G. M. Jelsma (6298130)
Sharon Kean (458309)
Nicolas Lemyre (6298133)
David W. Loudon (6298136)
Lisa Macaulay (6298139)
Douglas J. Maxwell (6298142)
Alex McConnachie (104022)
Nanette Mutrie (53509)
Maria Nijhuis-van der Sanden (3506987)
Hugo V. Pereira (6298145)
Matthew Philpott (6298148)
Glyn C. Roberts (6298151)
John Rooksby (6298154)
Øystein B. Røynesdal (6298157)
Naveed Sattar (8785)
Marit Sørensen (6298160)
Pedro J. Teixeira (848483)
Shaun Treweek (62880)
Theo van Achterberg (5454581)
Irene van de Glind (6298163)
Willem van Mechelen (17577)
Hidde P. van der Ploeg (484286)

February 2019

Multiple imputed, unadjusted costs used by participants allocated to the EuroFIT programme immediate...

Valuation of cost items during the 12-month follow-up period (in Euro; 2016).

Ben F. M. Wijnen (4997315)
Bea Hemmen (3633202)
Ans I. E. Bouman (3633208)
Henk van de Meent (731131)
Ton Ambergen (295464)
Peter R. G. Brink (3633211)
Henk A. M. Seelen (563131)
Silvia M. A. A. Evers (643477)

March 2019

Valuation of cost items during the 12-month follow-up period (in Euro; 2016).</p

Basic characteristics and cumulative breast cancer treatment costs by stage (US dollars in 2015).

Li Sun (4624)
Rosa Legood (362486)
Isabel dos-Santos-Silva (528117)
Shivani Mathur Gaiha (6009653)
Zia Sadique (3487259)

November 2018

Basic characteristics and cumulative breast cancer treatment costs by stage (US dollars in 2015).</p

Costs and “extra costs” of brand, follow-on, generic, and total prescriptions in millions of Euros.

Nathalie Vernaz (289981)
Guy Haller (418190)
François Girardin (418191)
Benedikt Huttner (322756)
Christophe Combescure (146642)
Pierre Dayer (418192)
Daniel Muscionico (418193)
Jean-Luc Salomon (418194)
Pascal Bonnabry (418195)

June 2013

Costs and “extra costs” of brand, follow-on, generic, and total prescriptions in millions of Euro...

Cumulative cost of care ($CAD 2018, 95% CI) between sepsis cases and matched controls.

Michelle Tew (8725419)
Kim Dalziel (5237753)
Karin Thursky (4329955)
Murray Krahn (250684)
Lusine Abrahamyan (6291005)
Andrew M. Morris (4249600)
Philip Clarke (78600)

August 2021

Cumulative cost of care ($CAD 2018, 95% CI) between sepsis cases and matched controls.</p

“Extra costs” in millions of Euros, 95% CIs, and percent of total prescriptions for three scenarios.

Nathalie Vernaz (289981)
Guy Haller (418190)
François Girardin (418191)
Benedikt Huttner (322756)
Christophe Combescure (146642)
Pierre Dayer (418192)
Daniel Muscionico (418193)
Jean-Luc Salomon (418194)
Pascal Bonnabry (418195)

June 2013

“Extra costs” in millions of Euros, 95% CIs, and percent of total prescriptions for three scenari...

Cumulative outpatient main healthcare care costs since the index dates in different health states of HER2-positive breast cancer in Iran, during a 3-year follow-up period (21.3.2011–20.3.2014).

Amir Ansaripour (5807627)
Kazem Zendehdel (731058)
Niki Tadayon (5807630)
Fatemeh Sadeghi (832474)
Carin A. Uyl-de Groot (4370503)
W. Ken Redekop (5807633)

October 2018

Cumulative outpatient main healthcare care costs since the index dates in different health states of...

Differences in relapse or recurrence and costs over 12 months between S-PCT and TAU; ICER, CE-planes quadrants, and acceptability.

Karolien E. M. Biesheuvel-Leliefeld (6103085)
Judith E. Bosmans (162999)
Sandra M. A. Dijkstra-Kersten (6103088)
Filip Smit (186016)
Claudi L. H. Bockting (130818)
Digna J. F. van Schaik (6103091)
Harm W. J. van Marwijk (145838)
Henriette E. van der Horst (6103094)

December 2018

Differences in relapse or recurrence and costs over 12 months between S-PCT and TAU; ICER, CE-planes...

Observed mean annual costs per patient with chronic pain (in EUR for year 2016): Main analysis (n = 54) and sensitivity analysis (n = 33).

Susanne Mayer (3532715)
Jonah Spickschen (6490565)
K. Viktoria Stein (6490568)
Richard Crevenna (4976600)
Thomas E. Dorner (748649)
Judit Simon (4353796)

March 2019

Observed mean annual costs per patient with chronic pain (in EUR for year 2016): Main analysis (n = ...

Adjusted differences in mean yearly cumulative costs, treated vs. untreated, by cohort.

Bryan S. Michalowicz (16827899)
Jeffrey P. Anderson (16827902)
Thomas E. Kottke (13875140)
Steven P. Dehmer (6528569)
Donald C. Worley (15219980)
Sheryl Kane (16827905)
Sarah Basile (16827908)
D. Brad Rindal (12375537)

August 2023

Adjusted differences in mean yearly cumulative costs, treated vs. untreated, by cohort.</p

Felix Lötsch (625051)
Christine M. Budke (116245)
Herbert Auer (14621)
Klaus Kaczirek (811816)
Fredrik Waneck (6281387)
Heimo Lagler (297548)
Michael Ramharter (297552)

January 2019

Average AE-related costs in the year of diagnosis and the two subsequent years.</p

Multiple imputed and pooled costs after 6 months follow-up in the usual care and interventioun groups and mean differences between groups (95% CI) (unadjusted analysis).

Maria Rubio-Valera (444245)
Judith Bosmans (444246)
Ana Fernández (309521)
Maite Peñarrubia-María (444247)
Marian March (444248)
Pere Travé (444249)
Juan A. Bellón (444250)
Antoni Serrano-Blanco (87615)

August 2013

Multiple imputed and pooled costs after 6 months follow-up in the usual care and interventioun gr...

Cost-effectiveness acceptability curve showing probability that JCP+TAU is more cost-effective than TAU over 18-months follow-up.

Barbara Barrett (489210)
Waquas Waheed (489211)
Simone Farrelly (489212)
Max Birchwood (489213)
Graham Dunn (489214)
Clare Flach (489215)
Claire Henderson (489216)
Morven Leese (489217)
Helen Lester (164644)
Max Marshall (489218)
Diana Rose (342126)
Kim Sutherby (489219)
George Szmukler (489220)
Graham Thornicroft (44441)
Sarah Byford (405086)

November 2013

Cost-effectiveness acceptability curve showing probability that JCP+TAU is more cost-effective th...

Cumulative breast cancer treatment costs by stages of in situ, local, regional and distant.

Li Sun (4624)
Rosa Legood (362486)
Isabel dos-Santos-Silva (528117)
Shivani Mathur Gaiha (6009653)
Zia Sadique (3487259)

November 2018

Cumulative breast cancer treatment costs by stages of in situ, local, regional and distant.</p

Observed mean annual costs per patient with chronic pain by sex and number of pain points (in EUR for year 2016) (n = 54).

Susanne Mayer (3532715)
Jonah Spickschen (6490565)
K. Viktoria Stein (6490568)
Richard Crevenna (4976600)
Thomas E. Dorner (748649)
Judit Simon (4353796)

March 2019

Observed mean annual costs per patient with chronic pain by sex and number of pain points (in EUR fo...

Multiple imputed, unadjusted costs used by participants allocated to the EuroFIT programme immediately (intervention) or after 12 months (comparison), and their unit costs (£, 2016) over 12-month follow-up.

Sally Wyke (3408131)
Christopher Bunn (5467193)
Eivind Andersen (6298112)
Marlene N. Silva (6298115)
Femke van Nassau (4518406)
Paula McSkimming (6298118)
Spyros Kolovos (6298121)
Jason M. R. Gill (206415)
Cindy M. Gray (6298124)
Kate Hunt (596973)
Annie S. Anderson (6298127)
Judith Bosmans (444246)
Judith G. M. Jelsma (6298130)
Sharon Kean (458309)
Nicolas Lemyre (6298133)
David W. Loudon (6298136)
Lisa Macaulay (6298139)
Douglas J. Maxwell (6298142)
Alex McConnachie (104022)
Nanette Mutrie (53509)
Maria Nijhuis-van der Sanden (3506987)
Hugo V. Pereira (6298145)
Matthew Philpott (6298148)
Glyn C. Roberts (6298151)
John Rooksby (6298154)
Øystein B. Røynesdal (6298157)
Naveed Sattar (8785)
Marit Sørensen (6298160)
Pedro J. Teixeira (848483)
Shaun Treweek (62880)
Theo van Achterberg (5454581)
Irene van de Glind (6298163)
Willem van Mechelen (17577)
Hidde P. van der Ploeg (484286)

February 2019

Multiple imputed, unadjusted costs used by participants allocated to the EuroFIT programme immediate...

Cumulative costs over the 6 months follow-up period by condition (CBTsa vs TAU), in 2015 Euros.

Abstract

Extracted data

Cumulative costs over the 6 months follow-up period by condition (CBTsa vs TAU), in 2015 Euros.

Abstract

Extracted data

Related items

Related items